Drug-eluting coronary stent very late thrombosis revisited

Herz

Volumn 33, Issue 5, 2008, Pages 334-342

  Lanzer, Peter ^a   Sternberg, Katrin ^b   Schmitz, Klaus Peter ^b   Kolodgie, Frank ^c   Nakazawa, Gaku ^c   Virmani, Renu ^c  

^a Hospitals and Clinics ^*  (Germany)

^b UNIVERSITY OF ROSTOCK   (Germany)

^c CVPATH INSTITUTE   (United States)

Author keywords

Drug eluting stents; Review of data; Risk reduction strategies; Stent thrombosis

Indexed keywords

ACETYLSALICYLIC ACID; ANTICOAGULANT AGENT; ANTIINFLAMMATORY AGENT; ANTITHROMBOCYTIC AGENT; CHITOSAN; FIBRIN; HEPARIN; HYALURONIC ACID; IMMUNOMODULATING AGENT; PACLITAXEL; POLY(3 HYDROXYBUTYRIC ACID); POLY(ORTHO ESTER); POLYCAPROLACTONE; POLYETHYLENE TEREPHTHALATE; POLYLACTIDE; POLYLYSINE; POLYMER; POLYMETHACRYLIC ACID; POLYURETHAN; RAPAMYCIN; SILICONE DERIVATIVE; THIENOPYRIDINE DERIVATIVE;

BARE METAL STENT; BIOCOMPATIBILITY; CLINICAL TRIAL; CONTINUOUS INFUSION; CORONARY STENT; DRUG ELUTING STENT; HUMAN; IMPLANTATION; INCIDENCE; NONHUMAN; PACLITAXEL ELUTING STENT; PATIENT IDENTIFICATION; PROGNOSIS; RESTENOSIS; REVIEW; RISK FACTOR; RISK REDUCTION; SIROLIMUS ELUTING STENT; STENT; SURGICAL TECHNIQUE; THROMBOSIS;

CORONARY STENOSIS; CORONARY THROMBOSIS; DRUG-ELUTING STENTS; HUMANS;

EID: 51349102226     PISSN: 03409937     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00059-008-3080-x     Document Type: Review

References (90)

1. Update to FDA statement on coronary drug-eluting stents. http://www.fda.gov/cdrh/news/010407.html (accessed January 19, 2007).
2. Hill R, Bagust A, Bakhai A, et al. Coronary artery stents: a rapid systematic review and economic evaluation. Health Technol Assess 2004;8:-242.
3. Serruys PW, Kutryk MJ, Ong AT. Coronary-artery stents. N Engl J Med 2006;354:483-95.
4. Farb A, Burke AP, Kolodgie FD, et al. Pathological mechanisms of fatal late coronary stent thrombosis in humans. Circulation 2003;108:1701-6.
5. Kaiser C, Brunner-La Rocca HP, Buser PT, et al. Incremental cost-effectiveness of drug-eluting stents compared with third-generation bare-metal stent in a real-world setting: randomised Basel Stent Kosten Effektivitäts Trial (BASKET). Lancet 2005;366:921-9.
6. http://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfadvisory/details.cfm? mtg=672-5 (accessed July 10, 2008).
7. Cutlip DE, Windecker S, Mehran R, et al., on behalf of the Academic Research Consortium. Clinical end points in coronary stent trials: a case for standardized definitions. Circulation 2007;115:2344-51.
8. Fischman DL, Leon MB, Baim DS, et al., for the Stent Restenosis Study Investigators. A randomized comparison of coronary-stent placement and balloon angioplasty in the treatment of coronary artery disease. N Engl J Med 1994;331:496-501.
9. Serruys PW, de Jaegere P, Kiemeneij F, et al., for the BENETEST Study Group. A comparison of balloon-expandable-stent implantation with balloon angioplasty in patients with coronary artery disease. N Engl J Med 1994;331:489-95.
10. Schomig A, Neumann FJ, Kastrati A, et al. A randomized comparison of antiplatelet and anticoagulation therapy after the placement or coronary-artery stents. N Engl J Med 1996;334:1084-9.
11. Leon M, Baim D; Popma J, et al. A clinical trial comparing three anti-thrombotic-drug regimens after coronary-artery stenting. Stent Anticoagulation Restenosis Study Investigators. N Engl J Med 1998;339:1665-7.
12. Bertrand ME, Rupprecht HJ, Urban P, et al. Double-bind study of the safety of clopidogrel with and without a loading dose of combination with aspirin compared with ticlopidine in combination with aspirin after coronary stenting: the Clopidogrel Aspirin Stent International Cooperative Study (CLASSICS). Circulation 2000;102:624-9.
13. Colombo A, Hall P, Nakamura S, et al. Intracoronary stenting without anticoagulation accomplished with intravascular ultrasound guidance. Circulation 1995;91:1676-88.
14. Nakamura S, Hall P, Gaglione A, el al. High pressure assisted coronary stent implantation accomplished without intravascular ultrasound guidance and subsequent anticoagulation. J Am Coll Cardiol 1997;29:21-7.
15. Campbell R, Edelman ER. Endovascular stent design dictates experimental restenosis and thrombosis. Circulation 1995;91:2995-3001.
16. Angiolillo DJ, Fernandez-Ortiz A, Bernardo E, et al. High clopidogrel loading dose during coronary stenting: effects on drug response and interindividual variability. Eur Heart J 2004;25:1903-10.
17. Wiviott SD, Braunwald E, McCabe CH, et al. Prasugrel versus clopidogrel in patients with acute coronary syndromes. N Engl J Med 2007;357:2001-15.
18. Eisenstein EL, Anstorm KJ, Kong DF, et al. Clopidogrel use and long-term clinical outcomes after drug-eluting stent implantation. JAMA 2007;297:159-68.
19. Cutlip DE, Baim DS, Ho KK, et al. Stent thrombosis in the modern era: a pooled analysis of multicenter coronary stent clinical trials. Circulation 2001;103:1967-71.
20. Wenaweser P, Rey C, Eberli FR, et al. Stent thrombosis following bare-metal stent implantation: success of emergency percutaneous coronary intervention and predictors of adverse outcome. Eur Heart J 2005;26:1180-7.
21. Costa MA, Sabaté M, van der Giessen WJ, et al. Late coronary occlusion after intracoronary brachytherapy. Circulation 1999;100:789-92.
22. Jeremias A, Sylvia B, Bridges J, et al. Stent thrombosis after successful sirolimus-eluting stent implantation. Circulation 2004;109:1930-2.
23. McFadden EP, Stabile E, Regar E, et al. Late thrombosis in drug-eluting coronary stents after discontinuation of antiplatelet therapy. Lancet 2004;364:1519-21.
24. Holmes DR Jr, Moses JW, Schofer J, et al. Cause of death with bare metal and sirolimus-eluting stents. E Heart J 2006;27:2815-22.
25. Pfisterer M, Brunner-LaRocca HP, Buser PT, et al., for the BASKET-LATE Investigators. Late clinical events after clopidogrel discontinuation may limit the benefit of drug-eluting stents. An observational study of drug-eluting versus bare-metal stents. J Am Coll Cardiol 2006;48:2584-91.
26. Moreno R, Fernandez C, Hernandez R, et al. Drug-eluting stent thrombosis. J Am Coll Cardiol 2005;45:954-9.
27. Nordmann AJ, Briel M, Bucher HC. Mortality in randomized controlled trials comparing drug-eluting vs. bare metal stents in coronary artery disease: a meta-analysis. E Heart J 2006;27:2784-814.
28. Windecker S, Meier B. Late coronary stent thrombosis. Circulation 2007;116:1952-65.
29. Kuchulakanti PK, Chu WW, Torgusson R, et al. Correlates and long-term outcomes of angiographically proven stent thrombosis with sirolimus- and paclitaxel-eluting stents. Circulation 2006;113:1108-13.
30. Daemen J, Wenaweser P, Tsuchida K, et al. Early and late coronary stent thrombosis of sirolimus-eluting and paclitaxeleluting stents in routine clinical practice. Lancet 2007;369:667-8.
31. Iakovou I, Schmidt T, Bonizzoni E, et al. Incidence, predictors, and outcome of thrombosis after successful implantation of drug-eluting stents. JAMA 2005;293:2126-30.
32. Ajzenberg N, Aubry P, Huisse MG, et al. Enhanced shear-induced platelet aggregation in patients who experience subacute stent thrombosis. J Am Coll Cardiol 2005;45:1753-6.
33. Wenaweser P, Dorffler-Melly J, Imboden K, et al. Stent thrombosis is associated with an impaired response to antiplatelet therapy. J Am Coll Cardiol 2005;45:1748-52.
34. Ferrari E, Benhamour M, Cerboni P, et al. Coronary syndromes following aspirin withdrawal. J Am Coll Cardiol 2005;45:456-9.
35. Reaume KT, Regal RE, Dorsch MP. Indications for dual antiplatelet therapy with aspirin and clopidogrel: evidence-based recommendations of use. Ann Pharmacother 2008;42:550-7.
36. Brar SS, Kim J, Brar SK, et al. Long-term outcomes by clopidogrel duration and stent type in diabetic population with de novo coronary artery lesions. J Am Coll Cardiol 2008;51:2220-7.
37. Lanzer P, Topoleski T. Coronary arteries. In: Lanzer P, ed. Mastering endovascular techniques; guide to excellence. Philadelphia: Lippincott, Williams & Wilkins, 2006:273-9.
38. Lincoff AM, Furst JG, Ellis SG, et al. Sustained local delivery of dexamethasone by a novel intravascular eluting stent to prevent restenosis in the porcine coronary injury model. J Am Coll Cardiol 1997;29:808-16.
39. Van der Giessen WJ, Lincoff AM, Schwartz RS, et al. Marked inflammatory sequelae to implantation of biodegradable and nonbiodegradable polymers in porcine coronary arteries. Circulation 1996;94:1690-7.
40. Rogers C, Karnovsky MJ, Edelman ER. Inhibition of experimental neointimal hyperplasia and thrombosis depends on the type of vascular injury and the site of drug administration. Circulation 1993;88:1215-21.
41. Drachman DE, Edelman ER, Seifert P, et al. Neointimal thickening after stent delivery of paclitaxel: change in composition and arrest of growth over six months. J Am Coll Cardiol 2000;36:2325-32.
42. Farb A, Heller PF, Shroff S, et al. Pathological analysis of local delivery of paclitaxel via a polymer-coated stent. Circulation 2001;104:473-9.
43. Carter AJ, Aggarwal M, Kopia GA, et al. Long-term effects of polymer-based, slow-release, sirolimus-eluting stents in a porcine coronary model. Cardiovasc Res 2004;63:617-24.
44. Sousa JE, Costa MA, Abizaid A, et al. Lack of neointimal proliferation after implantation of sirolimus-coated stents in human coronary arteries: a quantitative coronary angiography and three-dimensional intravascular ultrasound study. Circulation 2001;103:192-5.
45. Morice MC, Serruys PW, Sousa JE, et al. A randomized comparison of a sirolimus-eluting stent with a standard stent for coronary revascularization. N Engl J Med 2002;346:1773-80.
46. Guagliumi G, Farb A, Musumeci G, et al. Images in cardiovascular medicine. Sirolimus-eluting stent implanted in human coronary artery for 16 months: pathological findings. Circulation 2003;107:1340-1.
47. Virmani R, Guagliumi G, Farb A, et al. Localized hypersensitivity and late coronary thrombosis secondary to a sirolimus-eluting stent: should we be cautious? Circulation 2004;109:701-5.
48. Finn AV, Kolodgie FD, Harnek J, et al. Differential response of delayed healing and persistent inflammation at sites of overlapping sirolimus- or paclitaxel-eluting stents. Circulation 2005;112:270-8.
49. Joner M, Finn AV, Farb A, et al. Pathology of drug-eluting stents in humans: delayed healing and late thrombotic risk. J Am Coll Cardiol 2006;48:193-202.
50. Lambert TL, Dev V, Rechavia E, et al. Localized arterial wall drug delivery from a polymer-coated removable metallic stent. Kinetics, distribution, and bioactivity of forskolin. Circulation 1994;90:1003-11.
51. Hou D, Narciso H, Kamdar K, et al. Stent-based nitric oxide delivery reducing neointimal proliferation in a porcine carotid overstretch injury model. Cardiovasc Intervent Radiol 2005;28:60-5.
52. De Scheerder I, Wang K, Wilczek K, et al. Local methylprednisolone inhibition of foreign body response to coated intracoronary stents. Coron Artery Dis 1996;7:161-6.
53. Unverdorben M, Degenhardt R, Sick P, et al. Evaluation of the Coroflex Theca-Stent for reduction of restenosis (ECORI). J Invasive Cardiol 2005;17:199-202.
54. Suzuki T, Kopia G, Hayashi S, et al. Stent-based delivery of sirolimus reduces neointimal formation in a porcine coronary model. Circulation 2001;104:1188-93.
55. Schellhammer F, Walter M, Berlis A, et al. Polyethylene terephthalate and polyurethane coatings for endovascular stents: preliminary results in canine experimental arteriovenous fistulas. Radiology 1999; 211:169-75.
56. Banai S, Gertz SD, Gavish L, et al. Tyrphostin AGL-2043 eluting stent reduces neointima formation in porcine coronary arteries. Cardiovasc Res 2004;64:165-71.
57. Sternberg K, Kramer S, Nischan C, et al. In vitro study of drug-eluting stent coatings based on poly(L-lactide) incorporating cyclosporine A - drug release, polymer degradation and mechanical integrity. J Mater Sci Mater Med 2007;18:1423-32.
58. Holmes DR, Camrud AR, Jorgenson MA, et al. Polymeric stenting in the porcine coronary artery model: differential outcome of exogenous fibrin sleeves versus polyurethane-coated stents. J Am Coll Cardiol 1994;24:525-31.
59. Huang LY, Yang MC. Hemocompatibility of layer-by-layer hyaluronic acid/heparin nanostructure coating on stainless steel for cardiovascular stents and its use for drug delivery. J Nanosci Nanotechnol 2006;6:3163-70.
60. Thierry B, Merhi Y, Silver J, et al. Biodegradable membrane-covered stent from chitosan-based polymers. J Biomed Mater Res A 2005;75:556-66.
61. Billinger M, Buddeberg F, Hubbell JA, et al. Polymer stent coating for prevention of neointimal hyperplasia. J Invasive Cardiol 2006;18:423-6, discussion 427.
62. Beythien C, Gutensohn K, Bau J, et al. Influence of stent length and heparin coating on platelet activation: a flow cytometric analysis in a pulsed floating model. Thromb Res 1999;94:79-86.
63. Lewis AL, Vick TA, Collias AC, et al. Phosphorylcholine-based polymer coatings for stent drug delivery. J Mater Sci Mater Med 2001;12:865-70.
64. Sousa JE, Serruys PW, Costa MA. New frontiers in cardiology: drug-eluting stents. Parts I and II. Circulation 2003;107:2274-9 (Part I), 2383-9 (Part II).
65. Salu KJ, Bosmans JM, Bult H, et al. Drug-eluting stents: a new treatment in the prevention of restenosis. Part II: Clinical studies. Acta Cardiol 2004;59:165-77.
66. Schwartz RS, Edelman E, Carter A, et al. Drug-eluting stents in preclinical studies: recommended evaluation from a consensus group. Circulation 2002;106:1867-73.
67. Regar E, Sianos G, Serruys PW. Stent development and local drug delivery. Br Med Bull 2001;59:227-48.
68. Ranade SV, Miller KM, Richard RE, et al. Physical characterization of controlled release of paclitaxel from the TAXUS Express2 drug-eluting stent. J Biomed Mater Res A 2004;71:625-34.
69. Daemen J, Serruys PW. Drug-eluting stent update 2007. Part I. A survey of current and future generation drug-eluting stents: meaningful advances or more of the same? Part II. Unsettled issues. Circulation 2007;116:316-28 (Part I), 961-8 (Part II).
70. Boland JL, Corbeij HA, Van Der Giessen W, et al. Multicenter evaluation of the phosphorylcholine-coated biodivYsio stent in short de novo coronary lesions: the SOPHOS study. Int J Cardiovasc Intervent 2000;3:215-25.
71. Saito T, Iguchi A, Sakurai M, et al. Biomechanical study of a poly-L-lactide (PLLA) sternal pin in sternal closure after cardiothoracic surgery. Ann Thorac Surg 2004;77:684-7.
72. Makela P, Pohjonen T, Tormala P, et al. Strength retention properties of self-reinforced poly L-lactide (SR-PLLA) sutures compared with polyglyconate (Maxon) and polydioxanone (PDS) sutures. An in vitro study. Biomaterials 2002;23:2587-92.
73. Nguyen KT, Su SH, Sheng A, et al. In vitro hemocompatibility studies of drug-loaded poly-(L-lactic acid) fibers. Biomaterials 2003;24:5191-201.
74. Lewis DH. Controlled release of bioactive agents from lactide/glycolide polymers. In: Chasin M, Langer R, eds. Biodegradable polymers as drug delivery systems, vol 45. New York: Dekker, 1990:1-8.
75. Multanen M, Tammela TL, Laurila M, et al. Biocompatibility, encrustation and biodegradation of ofloxacine and silver nitrate coated poly-L-lactic acid stents in rabbit urethra. Urol Res 2002;30:227-32.
76. Sternberg K, Selent C, Hakansson N, et al. Bioartificial materials in urology. Urologe A 2004;43:1200-7.
77. Bunger CM, Grabow N, Kroger C, et al. Iliac anastomotic stenting with a sirolimus-eluting biodegradable poly-L-lactide stent: a preliminary study after 6 weeks. J Endovasc Ther 2006;13:630-9.
78. Krucoff MW, Kereiakes DJ, Petersen JL, et al., COSTAR II Investigators Group. A novel bioresorbable polymer paclitaxel-eluting stent for the treatment of single and multivessel coronary disease: primary results of the COSTAR (Cobalt Chromium Stent With Antiproliferative for Restenosis) II study. J Am Coll Cardiol 2008;51:1543-52.
79. Vogt F, Stein A, Rettemeier G, et al. R. Long-term assessment of a novel biodegradable paclitaxel-eluting coronary polylactide stent. Eur Heart J 2004;25:1330-40.
80. Uurto I, Mikkonen J, Parkkinen J, et al. Drug-eluting biodegradable poly-D/L-lactic acid vascular stents: an experimental pilot study. J Endovasc Ther 2005;12:371-9.
81. Peuster M, Hesse C, Schloo T, et al. Long-term biocompatibility of a corrodible peripheral iron stent in the porcine descending aorta. Biomaterials 2006;27:4955-62.
82. Heublein B, Rohde R, Kaese V, et al. Biocorrosion of magnesium alloys: a new principle in cardiovascular implant technology? Heart 2003;89:651-6.
83. Tamai K, Igaki E, Kyo K, et al. Initial and 6-month results of biodegradable poly-l-lactic acid coronary stents in humans. Circulation 2000;102:399-404.
84. Tsuji T, Tamai H, Igaki K, et al. The influence of biodegradation of the biodegradable stent on vessel in long-term period: serial intravascular ultrasound analysis of the Igaki-Tamai biodegradable stent. Circulation 2002;106:Suppl:1778.
85. Biamino G. Biodegradable stents in the SFA: are they the answer? International Symposium on Endovascular Therapy, Miami Beach, FL, January 24, 2006.
86. Ormiston JA, Serruys PW, Regar E, et al. A bioabsorbable everolimus-eluting coronary stent system for patients with single de-novo coronary artery lesions (ABSORB): a prospective open-label trial. Lancet 2008;371:899-907.
87. Di Mario C, Griffiths H, Goktekin O, et al. Drug-eluting bioabsorbable magnesium stent. J Interv Cardiol 2004;17:391-5.
88. Waksman R. Update on bioabsorbable stents: from bench to clinical. J Interv Cardiol 2006;19:414-21.
89. Eggebrecht H, Rodermann J, Hunold P, et al. Images in cardiovascular medicine. Novel magnetic resonance-compatible coronary stent: the absorbable magnesium-alloy stent. Circulation 2005;112:e303-4.
90. Aoki J, Serruys PW, van Beusekom H, et al. Endothelial progenitor cell capture by stents coated with antibody against CD34: the HEALING-FIM (Healthy Endothelial Accelerated Lining Inhibits Neointimal Growth-First In Man) Registry. J Am Coll Cardiol 2005;45:1574-9.